Your fact-checks will appear here
Biotechnology company from Germany
Vaccine manufacturers do make from vaccines, but the scale and context vary by company, product, and time period; COVID‑19 vaccines produced especially large revenues and profits for major firms durin...
The assembled evidence identifies as the most consistently observed rare long-term adverse events associated with the Pfizer-BioNTech BNT162b2 vaccine, particularly after mRNA dosing in younger age gr...
Clinical-trial and post‑authorization reports for the 2024–2025 updated COVID vaccines show predictable, mostly short‑lived reactions — injection‑site pain/tenderness, fatigue, muscle aches, fever, he...
Dr. David E. Martin is presented in the provided materials as a researcher who links historical coronavirus cultivation, patents, and pandemic-era policy decisions to suspicions about COVID-19 origins...
Patients can check vaccination cards, vial labels and batch numbers to help confirm they received a listed COVID-19 product; national guidance and manufacturer materials routinely tie product names (e...
Pfizer’s COVID-19 mRNA vaccine uses lipid nanoparticles — a nanotechnology delivery system — and that approach is credited with enabling real-world protection measured across billions of doses (Pfizer...
Updated 2025–2026 COVID-19 boosters most commonly cause short-lived, mild-to-moderate reactions such as injection‑site pain, fatigue, fever, chills and headache; these are described in multiple patien...
Major COVID-19 vaccine platforms differ on preservatives, adjuvants and use of fetal‑derived cell lines: mRNA vaccines (Pfizer–BioNTech, Moderna) do not use traditional vaccine adjuvants and were not ...
There is no single public, consumer-facing Pfizer database that lets you enter a lot number and get full manufacturer records; multiple guidance pages and reporting routes instead point users to vacci...
In 2020 several COVID‑19 vaccine candidates completed large phase‑3 (or phase‑2/3 seamless) trials and reported high efficacy against symptomatic disease: Pfizer–BioNTech’s BNT162b2 reported about 95%...
Clinical and surveillance reporting through 2024–2025 shows the Pfizer–BioNTech (Comirnaty) COVID-19 vaccine routinely causes short-lived local reactions (arm pain) and systemic effects (fatigue, feve...
Peer‑reviewed population studies and systematic reviews consistently show myocarditis after mRNA COVID‑19 vaccination is rare, concentrated among adolescent and young adult males—most commonly within ...
Bill Gates and the Bill & Melinda Gates Foundation have a recorded history of investing in and funding biotech firms and platforms that touch cell therapies, gene editing and therapeutics — including ...
The Pfizer‑BioNTech COVID‑19 vaccine sold as Comirnaty is an mRNA vaccine whose core component is a nucleoside‑modified messenger RNA encoding the SARS‑CoV‑2 spike protein; regulators and manufacturer...
Large surveillance studies and systematic reviews find that Guillain–Barré syndrome (GBS) after COVID-19 vaccination is rare but that risk varies by vaccine platform: adenoviral‑vector vaccines (e.g.,...
Research shows SARS‑CoV‑2 spike protein can persist in brain-border tissues after infection and be linked to neuroinflammation in animal models and human samples; several teams report that prior mRNA ...
Available reporting and studies from 2024–2025 show that most 2025 booster formulations (mRNA and protein‑subunit types) produce short‑lived local and systemic side effects — typically soreness, fatig...
You asked for the full ingredient lists for Moderna and Janssen COVID‑19 vaccines and how they differ from Pfizer’s; available reporting in the provided sources discusses vaccine brands, approvals, an...
Governments generally do not impose universal legal caps on vaccine maker profits; instead, a mixture of procurement contracts, subsidies, liability protections, and market dynamics shape revenue and ...
The 2020 clinical trials showed , with BNT162b2 (Pfizer–BioNTech) demonstrating approximately in the pivotal trial and similar results for Moderna’s mRNA-1273 in phase III results; trials reported saf...